Join us at booth H7C19
Intermittent Hypoxic-Hyperoxic Training During Inpatient Rehabilitation Improves Exercise Capacity and Functional Outcome in Patients With Long Covid: Results of a Controlled Clinical Pilot Trial
We are thrilled to announce the publication of a major clinical study conducted at MEDIAN Klinik Flechtingen, showcasing the benefits of ReOxy® for patients with long COVID.
ReOxy® Featured in Newly Published Long-COVID Study
We are thrilled to announce the publication of a major clinical study conducted at MEDIAN Klinik Flechtingen, showcasing the benefits of ReOxy® for patients with long COVID.
Unveiling the Benefits of controlled hypoxia
In this article, we delve into the positive effects of intermittent hypoxia and explore the underlying mechanisms driving these benefits.
ESC Congress 2023, Amsterdam
This year, Ai Mediq had the privilege of participating in the European Society of Cardiology (ESC) Congress held in the city of Amsterdam. This prestigious congress brings together experts from private and public institutions worldwide to exchange knowledge and discoveries in the realm of cardiovascular medicine.
Clinical trial outcomes for rehab after COVID
ReOxy therapy and standard rehabilitation has been shown to be as almost twice as effective compared to the standard rehabilitation (83.6 m vs 44.6 m, p<0.001).
EULAR 2022 Congress
The results of the application of ReOxy therapy in patients with osteoarthritis and post-covid syndrome has been demonstrated during the presentation at Eular22
ReOxy at the University in Magdeburg
The team led by Prof. Schega from the Department of Health and Physical Activity at the Otto von Guericke University in Magdeburg (Faculty of Human Sciences, Institute III, Sports Sciences) is currently conducting the clinical study “Effects of intermittent hypoxia-hyperoxia on cognitive function, mobility and wellbeing in patients with dementia”
Multiple Sclerosis
Ai Mediq S.A. is pleased to announce the new stage of scientific cooperation with the Universitätsklinikum Hamburg-Eppendorf (UKE). Together with Dr. Sina Cathérine Rosenkranz we will be looking into potential perspectives of Interval Hypoxic Therapy in the treatment of multiple sclerosis.
Cardiac Rehabilitation of Elderly – New Trial in Italy
Last Friday (26th of July 2019) one of the most recent clinical trials involving ReOxy has been registered with CliniclTrials.gov database with NCT04034082 identifier.